{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:29:52Z","timestamp":1774517392354,"version":"3.50.1"},"reference-count":54,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-CD20 therapy is a highly effective multiple sclerosis (MS) disease-modifying therapy, but may be complicated by infections, which has led to the utilization of different extended interval dosing (EID) regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of standard interval dosing (SID) and EID of anti-CD20 therapy in MS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed and MS conference abstracts and included all studies comparing distinct cohorts of people with MS (PwMS) treated with SID and EID of anti-CD20 therapy that reported \u22651 efficacy or safety outcome measure. A meta-analysis was performed with effect size calculation (log odds ratio [logOR]) of efficacy and safety outcome measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventeen studies comparing SID to EID were identified, with 1739 (SID) and 1856 (EID) participants. There was no significant difference in frequencies of PwMS with relapses (logOR\u2009=\u20090.15;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.37), MRI activity (logOR\u2009=\u20090.05;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.7), no evidence of disease activity \u22123 (logOR\u2009=\u20090.33;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.33), serious infections (logOR\u2009=\u20090.46;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.16), and hypogammaglobulinemia G (logOR\u2009=\u2009\u22120.24;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.76).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Data from observational studies suggests that EID of anti-CD20 therapy may have a comparable efficacy and safety profile compared to SID.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20552173261432453","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:28:07Z","timestamp":1774340887000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of extended versus standard interval dosing of anti-CD20 therapy in multiple sclerosis \u2013 A meta-analysis"],"prefix":"10.1177","volume":"12","author":[{"given":"Mahmoud","family":"Elkhooly","sequence":"first","affiliation":[{"name":"Department of Neurology, Southern Illinois University School of Medicine, Springfield, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0694-5580","authenticated-orcid":false,"given":"Rhea","family":"Jacob","sequence":"additional","affiliation":[{"name":"Department of Neurology, College of Medicine, University of Florida, Gainesville, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0538-1378","authenticated-orcid":false,"given":"Torge","family":"Rempe","sequence":"additional","affiliation":[{"name":"Department of Neurology, College of Medicine, University of Florida, Gainesville, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02011-w"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201904"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52229"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102279"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00448-x"},{"issue":"1","key":"e_1_3_2_11_2","article-title":"Risk factors for serious infections in patients with MS receiving long-term ocrelizumab treatment: multivariate analyses","volume":"29","author":"Derfuss T","year":"2022","unstructured":"Derfuss T, et al. Risk factors for serious infections in patients with MS receiving long-term ocrelizumab treatment: multivariate analyses. Eur J Neurol 2022; 29(Suppl 1): EPO-403.","journal-title":"Eur J Neurol"},{"issue":"2","key":"e_1_3_2_12_2","first-page":"20","article-title":"Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions","volume":"25","author":"Derfuss T","year":"2019","unstructured":"Derfuss T, et al. Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Mult Scler 2019; 25(Suppl 2): 20\u20131.","journal-title":"Mult Scler"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000700"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104581"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01383-4"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200094"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231208311"},{"key":"e_1_3_2_18_2","first-page":"235","article-title":"Targeting CD20 in multiple sclerosis \u2013 review of current treatment strategies","volume":"57","author":"Chmielewska N","year":"2023","unstructured":"Chmielewska N, Szyndler J. Targeting CD20 in multiple sclerosis \u2013 review of current treatment strategies. Neurol Neurochir Pol 2023; 57: 235\u2013242.","journal-title":"Neurol Neurochir Pol"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12584-x"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211065711"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12273-9"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.109894"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520946017"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/20552173211062142"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1086028"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103364"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/20552173211013831"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211028833"},{"key":"e_1_3_2_29_2","article-title":"Sustained low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis","volume":"10","author":"Starvaggi Cucuzza C","year":"2022","unstructured":"Starvaggi Cucuzza C, et al. Sustained low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2022; 10: e200056.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000825"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200152"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241250199"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585241245296"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2023.05.001"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02900-z"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231223069"},{"key":"e_1_3_2_37_2","first-page":"126","article-title":"De-escalation of anti-CD20 monoclonal antibodies to low-moderate efficacy disease-modifying treatments (DMTs) in patients with relapse-remitting multiple sclerosis: an initial Iranian experience","volume":"16","author":"Paybast S","year":"2024","unstructured":"Paybast S, Rezaeimanesh N, Moghadasi AN. De-escalation of anti-CD20 monoclonal antibodies to low-moderate efficacy disease-modifying treatments (DMTs) in patients with relapse-remitting multiple sclerosis: an initial Iranian experience. Caspian J Intern Med 2024; 16: 126.","journal-title":"Caspian J Intern Med"},{"key":"e_1_3_2_38_2","volume-title":"Early extended dosing interval for rituximab in multiple sclerosis","author":"Fossum MT","year":"2024","unstructured":"Fossum MT. Early extended dosing interval for rituximab in multiple sclerosis. NTNU, 2024."},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00554"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105028"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001035"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15891"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01289-6"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X22666231002142709"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12084-4"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103287"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25105353"},{"key":"e_1_3_2_48_2","unstructured":"Perugini J Belley M Roux T. OPERA-ting differently. Presented at the ECTRIMS. 2022 October 12."},{"key":"e_1_3_2_49_2","unstructured":"Hauser S Ludwig Kappos GG Oh J et al. Efficacy and safety of a body-weight\u2013adjusted high dose of ocrelizumab vs standard dose in PPMS: primary results of the Phase IIIb GAVOTTE study. In: ECTRIMS. 2025."},{"key":"e_1_3_2_50_2","article-title":"Rationale and design of two Phase IIIb studies of ocrelizumab at higher than the approved dose in patients with RMS and PPMS","volume":"26","author":"Hauser S","year":"2020","unstructured":"Hauser S, et al. Rationale and design of two Phase IIIb studies of ocrelizumab at higher than the approved dose in patients with RMS and PPMS. Actrims Online Library 2020; 26: P0230.","journal-title":"Actrims Online Library"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200211"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22019"},{"key":"e_1_3_2_53_2","article-title":"Comprehensive analysis of B cell repopulation in ocrelizumab-treated patients with multiple sclerosis by mass cytometry and proteomics","volume":"28","author":"Wang M","year":"2025","unstructured":"Wang M, et al. Comprehensive analysis of B cell repopulation in ocrelizumab-treated patients with multiple sclerosis by mass cytometry and proteomics. iScience 2025; 28.","journal-title":"iScience"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2024.578502"},{"key":"e_1_3_2_55_2","unstructured":"Svenningsson A Joachim Burman TF Salzer J et al. Rituximab long-term DOSE trial in Multiple Sclerosis \u2013 RIDOSE-MS. A phase 3 trial investigating extended dosing regimen of rituximab in relapsing-remitting MS. In:. ECTRIMS. 2025."}],"container-title":["Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552173261432453","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20552173261432453","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552173261432453","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:16:28Z","timestamp":1774512988000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20552173261432453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/20552173261432453"],"URL":"https:\/\/doi.org\/10.1177\/20552173261432453","relation":{},"ISSN":["2055-2173","2055-2173"],"issn-type":[{"value":"2055-2173","type":"print"},{"value":"2055-2173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"20552173261432453"}}